N-methoxydiphenyl methyl amine | 136580-21-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methoxydiphenyl methyl amine
• 英文别名: N-methoxybenzhydrylamine；N-methoxy-1,1-diphenylmethanamine
• CAS: 136580-21-7
• 化学式: C₁₄H₁₅NO
• mdl: MFCD23714755
• 分子量: 213.279
• InChiKey: RUTNWJPBQZSLNK-UHFFFAOYSA-N

物化性质

• 沸点：
  321.6±52.0 °C(Predicted)
• 密度：
  1.059±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-methoxydiphenyl methyl amine 在 苯基溴化镁 作用下， 以 乙醚 、 正己烷 为溶剂， 反应 0.25h， 以19%的产率得到(E)-N-benzylidenebenzenamine
  参考文献：
  名称：

  Novel Domino Elimination-Rearrangement-Addition Reaction of N-Alkoxy(arylmethyl)amines to N-Alkyl Arylamines

  摘要：

  一种新的 N-烷氧基（芳基甲基）胺生成 N-烷基芳基胺的多米诺反应，由三种类型的反应组成：醇的消除、芳基的重排以及有机锂或镁试剂的加成，已被开发用于第一次。

  DOI：

  10.1055/s-2006-949642
• 作为产物：
  描述：

  benzophenone oxime methyl ether 在 吡啶 、 盐酸 、 diborane(6) 作用下， 以 乙醇 为溶剂， 生成 N-methoxydiphenyl methyl amine
  参考文献：
  名称：

  Kawase,M.; Kikugawa,Y., Journal of the Chemical Society. Perkin transactions I, 1979, p. 643 - 645

  摘要：

  DOI：

文献信息

• GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS
  申请人：Dimarchi Richard D.

  公开号：US20100190699A1

  公开（公告）日：2010-07-29

  Modified glucagon peptides are disclosed having improved solubility while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.

  本发明公开了改性胰高血糖素肽，其具有改善的溶解性，同时保留了胰高血糖素激动剂活性。通过将天然氨基酸替换为带电氨基酸和/或在肽的羧基末端添加带电氨基酸，改性了糖原肽。改性的胰高血糖素激动剂可以进一步通过聚乙二醇化或选择来自序列号为20、21、23的羧基末端肽或两者的任意一种来增强胰高血糖素激动剂类似物的溶解性。
• GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS AND MICROSCALE SCANNING
  申请人：Thorson Jon S.

  公开号：US20130004979A1

  公开（公告）日：2013-01-03

  The present invention generally relates to materials and methods for exploiting glycosyltransferase reversibility for nucleotide diphosphate (NDP) sugar synthesis. The present invention provides engineered glycosyltransferase enzymes characterized by improved reaction reversibility and expanded sugar donor specificity as compared to corresponding non-mutated glycosyltransferase enzymes. Such reagents provide advantageous routes to NDP sugars for subsequent use in a variety of biomedical applications, including enzymatic and chemo-enzymatic glycorandomization.

  本发明一般涉及利用糖基转移酶可逆性合成核苷酸二磷酸（NDP）糖的材料和方法。本发明提供了改良反应可逆性并扩展糖供体特异性的工程糖基转移酶酶，与相应的非突变糖基转移酶酶相比，具有更好的反应可逆性和扩展的糖供体特异性。这些试剂提供了有利的NDP糖路线，用于随后在各种生物医学应用中使用，包括酶促和化学酶促糖随机化。
• Glucagon/GLP-1 receptor co-agonists
  申请人：Indiana University Research and Technology Corporation

  公开号：EP2487184A1

  公开（公告）日：2012-08-15

  Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. These modified glucagon co-agonist analogs may be combined with other anti-diabetic or anti-obesity compounds and used to control hyperglycemia, or to induce weight loss or prevent weight gain. In one embodiment the modified glucagon peptides comprise lactam bridges or substitution of the terminal carboxylic acid with an amide group. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR). Use of a glucagon/GLP-1 co-agonist for administration in combination with an anti-diabetic agent or anti-obesity agent.

  已公开的改良胰高血糖素肽在胰高血糖素受体上的效力比原生胰高血糖素更强。这些经修饰的胰高血糖素同系物类似物可与其他抗糖尿病或抗肥胖化合物结合使用，以控制高血糖，或诱导减肥或防止体重增加。在一个实施方案中，修饰的胰高血糖素肽包括内酰胺桥或用酰胺基取代末端羧酸。这些高效胰高血糖素类似物的溶解性和稳定性可通过对多肽进行聚乙二醇化修饰、羧基末端氨基酸的取代或添加选自 SEQ ID NO: 26（GPSSGAPPPS）、SEQ ID NO: 27（KRNRNNIA）和 SEQ ID NO: 28（KRNR）的羧基末端肽来进一步提高。使用胰高血糖素/GLP-1 协同激动剂与抗糖尿病药物或抗肥胖药物联合给药。
• Glucagon analogs exhibiting physiological solubility and stability
  申请人：Indiana University Research and Technology Corporation

  公开号：EP2570133A1

  公开（公告）日：2013-03-20

  Modified glucagon peptides are disclosed having improved solubility and stability, wherein the native glucagon has been modified by pegylation or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID No: 19, SEQ ID No: 20 and SEQ ID No: 21.

  已公开的修饰胰高血糖素肽具有更好的溶解性和稳定性，其中原生胰高血糖素已通过培基化或添加选自 SEQ ID No:19、SEQ ID No: 20 和 SEQ ID No: 21 所组成的组的羧基末端肽进行修饰。
• Glucagon/glp-1 receptor co-agonists
  申请人：Indiana University Research and Technology Corporation

  公开号：EP2676673A2

  公开（公告）日：2013-12-25

  Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).

  已公开的修饰胰高血糖素肽在胰高血糖素受体上的效力比原生胰高血糖素更强。通过形成分子内桥或用酰胺基团取代末端羧酸来进一步修饰胰高血糖素肽，可产生具有胰高血糖素/GLP-1 受体共激动剂活性的肽。这些高活性胰高血糖素类似物的溶解性和稳定性可通过对多肽进行聚乙二醇化、酰化、烷基化、羧基末端氨基酸的取代、C-末端截断或添加选自 SEQ ID NO: 26 (GPSSGAPPPS)、SEQ ID NO: 27 (KRNRNNIA) 和 SEQ ID NO: 28 (KRNR)的羧基末端肽来进一步改善。